Articles tagged "Heart"

2021 American Transplant Congress
Predicted Heart Mass Difference as a Risk Factor for Severe Primary Graft Dysfunction in the Contemporary Era of Heart Transplantation: A Report from the International Consortium on Primary Graft Dysfunction
F. Foroutan¹, L. K. Truby², Y. Moayedi¹, J. Han³, J. Guzman⁴, M. Farrero⁴, E. Baughan⁵, M. Farr⁵, H. Zafar⁶, J. Felius⁶, J. van Zyl⁷, D. Law⁸, S. Chih⁸, P. Angleitner⁹, M. Sabatino¹⁰, A. DeVore², R. J. Miller¹¹, L. Potena¹⁰, A. Zuckermann⁹, K. K. Khush³, S. A. Hall⁶, H. J. Ross¹
¹Ted Rogers Centre for Heart Research, Toronto, ON, Canada, ²Duke University School of Medicine, Durham, NC, ³Stanford University, Stanford, CA, ⁴Clinic Barcelona Hospital Universitari, Barcelona, Spain, ⁵Columbia University Medical Center, New York, NY, ⁶Baylor University Medical Center, Dallas, TX, ⁷Dallas University Medical Center, Dallas, TX, ⁸University of Ottawa Heart Institute, Ottawa, ON, Canada, ⁹Medical University of Vienna, Vienna, Austria, ¹⁰Bologna University Hospital, Bologna, Italy, ¹¹University of Calgary, Calgary, AB, Canada
*Purpose: Primary Graft Dysfunction (PGD) increases early mortality after heart transplant (HT). Predicted heart mass (PHM) difference may be a risk factor for PGD. Lack…
2021 American Transplant Congress
A Novel Mouse Model of Cardiac Allograft Vasculopathy
H. Tsuda¹, E. Reed², W. Baldwin¹, R. Fairchild¹
¹Inflammation and Immunity, Cleveland Clinic, Cleveland, OH, ²Pathology and Laboratory Medicine, University of California, Los Angeles, CA
*Purpose: Cardiac allograft vasculopathy (CAV) is a major long-term complication of heart transplantation and the presence of donor specific antibodies (DSA) is associated with an…
2021 American Transplant Congress
Effects of IL-2 and/ or Anti-IL6R Therapy on Long-term Cardiac Allograft Survival in Non-Human Primates (NHPs)
C. L. Miller, K. J. Ahrens, J. M. O, P. M. Patel, J. A. Morrissette, D. Becerra, T. Costa, A. Dehnadi, I. M. Hanekamp, G. Benichou, J. C. Madsen
Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA
*Purpose: Cardiac allograft tolerance in NHPs has been achieved by our group using a mixed chimerism model with allogeneic bone marrow transplant after non-myeloablative conditioning…
2021 American Transplant Congress
Association of Immune Cell Markers with Adverse Outcomes in the First 6 Months Post-pediatric Heart Transplantation
J. Chen¹, D. Salerno², H. Corbo¹, S. Shah³, A. Rothkopf⁴, I. D. Lytrivi⁴
¹Department of Pharmacy, Columbia University Irving Medical Center, New York, NY, ²Department of Pharmacy, Weill Cornell Medical Center, New York, NY, ³College of Pharmacy and Health Sciences, St. John's University, Queens, NY, ⁴Pediatric Cardiology, Columbia University Irving Medical Center, New York, NY
*Purpose: Immunosuppression titration post-orthotopic heart transplant (OHT) is limited to trough level monitoring and does not provide data pertaining to overall state of immunosuppression. Additional…
2021 American Transplant Congress
De Novo Donor Specific Antibodies After Heart Transplantation in Fontan Patients with Protein Losing Enteropathy
D. A. Magnetta¹, V. Hoch², D. Pinelli³, M. Monge⁴, E. Pahl¹, P. T. Thrush¹
¹Pediatric Cardiology, Lurie Children's Hospital, Chicago, IL, ²Northwestern School of Medicine, Chicago, IL, ³Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Pediatric Cardiothoracic Surgery, Lurie Children's Hospital, Chicago, IL
*Purpose: Protein Losing Enteropathy (PLE) complicates Fontan physiology and can be an indication for heart transplantation (HT). PLE is accompanied by immune dysregulation, potentially impacting…
2021 American Transplant Congress
Core Signature of Rejection-Specific Cytokines and Chemokines in Heart Biopsies After Transplantation
L. M. Radomsky¹, Y. Scheibner², J. F. Kuehne¹, J. Keil¹, K. Beushausen¹, K. Ludmilla², A. Schick², F. Ius², G. Warnecke³, C. Bara², C. S. Falk¹
¹Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany, ²Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany, ³Clinic for Cardiac Surgery, University of Heidelberg, Heidelberg, Germany
*Purpose: Allograft rejection remains one of the limiting factors for survival after HTX. The aim of this project was to characterize the cytokine/chemokine network in…
2021 American Transplant Congress
Association Between Cumulative Antithymocyte Globulin Dosing and Adverse Outcomes in Pediatric Heart Transplant Recipients
J. Chen¹, D. Salerno¹, H. Corbo¹, S. Shah², A. Rothkopf³, I. D. Lytrivi³
¹Department of Pharmacy, NewYork-Presbyterian Hospital, New York, NY, ²College of Pharmacy and Health Sciences, St. John's University, Queens, NY, ³Pediatric Cardiology, Columbia University Irving Medical Center, New York, NY
*Purpose: Lymphocyte depletion via rabbit antithymocyte globulin (rATG) is the most frequently used induction immunosuppressive in pediatric orthotopic heart transplant (OHT). Although outcomes are often…
2021 American Transplant Congress
Impact of New Onset Diabetes After Transplantation on Heart Transplant Recipients
W. Kang¹, W. Keattiyoat², M. Kim¹, C. Bhardwaj²
¹Department of Internal Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, ²Department of Cardiology, University of Illinois College of Medicine at Peoria, Peoria, IL
*Purpose: The purpose of this study is to investigate New Onset Diabetes After Transplantation (NODAT) incidence and its impact on post-transplant prognosis in adult heart…
2021 American Transplant Congress
The Gut Microbiome in Heart Transplantation: A Prospective Pilot Study
M. Dela Cruz¹, E. Littmann², R. Nayak², C. Lehmann², R. Keskey³, T. Baker³, H. Lin², A. Bennett¹, G. Kim¹, S. Pinney¹, E. Pamer², A. B. Nguyen¹
¹Cardiology, University of Chicago, Chicago, IL, ²Medicine, University of Chicago, Chicago, IL, ³Surgery, University of Chicago, Chicago, IL
*Purpose: The contribution of the intestinal microbiome to alloimmunity in heart transplantation (HT) is unknown. We examined the fecal microbiota of HT recipients at the…
2021 American Transplant Congress
Breakthrough Cytomegalovirus DNAemia in High vs Intermediate Risk Heart Transplant Recipients
G. Huang¹, O. E. Beaird¹, M. Davis², M. Carlson¹, S. Chang¹, P. Gaynor¹, A. Fan², M. Deng³, A. Multani¹, A. Nsair³, J. Schaenman¹
¹Infectious Diseases, UCLA, Los Angeles, CA, ²Pharmacy, UCLA, Los Angeles, CA, ³Cardiology, UCLA, Los Angeles, CA
*Purpose: Cytomegalovirus (CMV) is one of the most common infections after transplantation and continues to cause significant morbidity and mortality despite prophylaxis and screening strategies.…

« Previous Page
1
…
3
4
5
6
7
…
22
Next Page »